This study is for kids aged **12 to 17** who have chronic migraine. A migraine is a really bad headache that can make you feel sick or see things like flashing lights. The study wants to see if a medicine called eptinezumab helps reduce the number of days with migraines. Eptinezumab is given through a drip (IV infusion), which means it goes directly into your bloodstream. Participants will get one infusion of either eptinezumab at two different strengths or a placebo, which is a harmless saline solution. The study includes three parts: a 4-week screening period, 12 weeks of treatment, and an 8-week follow-up to ensure safety.
- Duration: Total of 24 weeks (6 months) including screening and follow-up.
- Visits: Includes a randomization visit where the treatment is decided.
- Eligibility: Participants must have had migraines for at least 6 months and fit other criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand